This approach can prompt the immunomodulatory response from MSCs in advance, resulting in the up-regulation of anti-inflammatory secretion [IL-10, IDO, cyclooxygenase (COX)-2, PGE-2, TSG-6, CCL12, chemokine (C-X-C Motif) ligand 2 (CXCL2), CCL4], and direct immune cell behaviors [59–66], which can lead to significantly improved therapeutic outcomes for MSCs in treating immune-related disorders in GVHD models [66, 67]. The gene discussed is CXCL2; the disease is graft versus host disease.